Abstract 5993
Background
Cancer patients undergoing chemotherapy who have Hepatitis B (HBV) infection may be at elevated risk of liver failure from HBV reactivation, resulting in treatment interruptions/delays, hospitalization, even liver transplantation and death. There is conflicting guidance regarding screening for HBV infection, given that the US Center for Disease Control recommends universal screening for all patients receiving cytotoxic or immunosuppressive therapies, whilst ASCO suggests a selective approach.
Methods
A screening initiative was set up from November 2010, with the aim of identifying patients with chronic infection and referring them for chemoprophylaxis to prevent re-activation. Patients prior to receiving chemotherapy, were offered HBV and HCV testing after being given information leaflets explaining the rationale and implications. Testing included HBsAg surface antigen, HBcAb core antibody, and for those –ve HBsAg and +ve HBcAb, viral load for HBV was recommended. HCV Abs were also tested. Patients HBsAg +ve, or HBcAb +ve and detectable viral load were referred for consideration of antiviral therapy, as were patients with +ve HCV Abs. Patients with Hepatocellular cancer and known Hepatitis infections were excluded from this analysis.
Results
1353 patients were screened between November 2010 and May 2015. With about 2.2% being positive for HBsAg, 14.8% for HBcAb and 1.2% for HepCAb, however with significant differences for gender and ethnicity. HepBcAb+ve: males 17.19% (99/576), females 12.78% (86/673). HepCAb +ve: Greek Cypriot 0.83% (9/1085), Turkish Cypriot 0% (0/49), Greeks 13.33% (2/15). Further data will be provided on the poster. In a sub-study for HepBcAb +ve but HepBsAg -ve, viral load was negative in 55 and positive in 3 patients. Of interest is that during this period two patients were diagnosed with Hepatitis re-activation, that were not part of this study; both patients had to stop chemotherapy and start anti-viral therapy.
Conclusions
This study confirms the low percentage of Hepatitis B and C infection in the Cyprus population, and that hepatitis re-activation although rare, is a real complication of chemotherapy. Patients born outside Cyprus have a higher incidence of HBV and HCV infections. The results are going to be used to set up local guidelines.
Clinical trial identification
Legal entity responsible for the study
Haris C. Charalambous.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1959 - Incidence and Survival among Young Women with Stage I-III Breast Cancer
Presenter: Alexandra Thomas
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4740 - Toxicity and Clinical Outcomes of Partial Breast Irradiation (PBI) Compared to Whole Breast Irradiation (WBI) for Early Stage Breast Cancer: A Systematic Review and Meta-analysis
Presenter: Hadar Goldvaser
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2092 - Should anthracyclines always be present in the adjuvant treatment of breast cancer (BC)? A systematic review and meta-analysis of randomized controlled trials (RCTs)
Presenter: Rafael Caparica
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5886 - Taxane & Cyclophosphamide vs Anthracycline & Taxane combination therapy as adjuvant treatment of breast cancer; a meta-analysis of randomized-controlled trials by the Hellenic Academy of Oncology (E.AK.O.)
Presenter: Panagiotis Ntellas
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2323 - Risk of cardiovascular late effects in breast cancer survivors: a population-based study
Presenter: Jihyoun Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2820 - Diagnostic Value of Contrast Enhanced Digital Mammography versus Contrast Enhanced MRI for Preoperative Evaluation of Breast Cancer
Presenter: Eun Young Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3739 - Relationship between androgen receptor and tumor infiltrating lymphocytes in triple negative breast cancer
Presenter: Luis Felipe Sánchez-Cousido
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4849 - Use of red clover in premenopausal breast cancer patients receiving hormonal adjuvant treatment: biological and clinical implications from a randomized clinical trial
Presenter: Cristina Ferraris
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2788 - PROMs following breast-conserving therapy for breast cancer: results from a prospective longitudinal monocentric study
Presenter: Isabelle Kindts
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4208 - Impact on disease-free survival (DFS) of the surgical waiting time (SWT) for patients (Pts) with early breast cancer (BC)
Presenter: RIKIYA Nakamura
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract